REGN-COV2
E579612
REGN-COV2 is a monoclonal antibody cocktail designed to prevent and treat COVID-19 by targeting the SARS-CoV-2 virus.
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
COVID-19 therapeutic
ⓘ
antiviral agent ⓘ monoclonal antibody cocktail ⓘ |
| administeredTo | non-hospitalized COVID-19 patients at high risk for severe disease ⓘ |
| alsoKnownAs |
REGEN-COV
NERFINISHED
ⓘ
REGN-COV NERFINISHED ⓘ REGN10933 and REGN10987 cocktail ⓘ |
| antibodyType | fully human monoclonal antibody ⓘ |
| belongsToClass |
combination monoclonal antibody therapies
ⓘ
neutralizing monoclonal antibodies ⓘ |
| clinicalTrialPhase |
Phase 1
ⓘ
Phase 2 ⓘ Phase 3 ⓘ |
| composition | fixed-dose combination of casirivimab and imdevimab ⓘ |
| designStrategy | antibody cocktail targeting non-overlapping epitopes ⓘ |
| developedBy | Regeneron Pharmaceuticals NERFINISHED ⓘ |
| developedFor |
post-exposure prophylaxis of COVID-19
ⓘ
pre-exposure prophylaxis of COVID-19 in certain populations ⓘ treatment of mild to moderate COVID-19 ⓘ |
| discoveredUsing | Regeneron VelocImmune platform NERFINISHED ⓘ |
| effectiveAgainst |
early SARS-CoV-2 variants such as D614G
ⓘ
early SARS-CoV-2 variants such as original Wuhan strain ⓘ |
| EUAGrantedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| EUAIndication |
post-exposure prophylaxis of COVID-19 in certain individuals
ⓘ
treatment of mild to moderate COVID-19 in high-risk outpatients ⓘ |
| EUAStatus | EUA later revoked or withdrawn in the United States due to variant resistance ⓘ |
| hasComponent |
casirivimab
ⓘ
imdevimab ⓘ |
| hasDrugName | casirivimab and imdevimab NERFINISHED ⓘ |
| indication |
prevention of COVID-19
ⓘ
treatment of COVID-19 ⓘ |
| mechanismOfAction |
blocks interaction between SARS-CoV-2 spike protein and ACE2 receptor
ⓘ
neutralizes SARS-CoV-2 by binding spike protein ⓘ |
| notIndicatedFor | patients requiring mechanical ventilation ⓘ |
| patentHolder | Regeneron Pharmaceuticals NERFINISHED ⓘ |
| rationale | use of two antibodies reduces risk of viral escape mutations ⓘ |
| reducedEffectivenessAgainst |
Omicron variant of SARS-CoV-2
NERFINISHED
ⓘ
some later SARS-CoV-2 variants ⓘ |
| regulatoryStatus | received Emergency Use Authorization from U.S. FDA ⓘ |
| routeOfAdministration |
intravenous infusion
ⓘ
subcutaneous injection ⓘ |
| targetOrganism | human ⓘ |
| targets |
SARS-CoV-2
NERFINISHED
ⓘ
SARS-CoV-2 spike protein NERFINISHED ⓘ receptor-binding domain of SARS-CoV-2 spike protein ⓘ |
| trialOutcome |
reduced COVID-19-related medical visits in high-risk outpatients
ⓘ
reduced risk of symptomatic infection in prophylaxis studies ⓘ reduced viral load in treated patients compared with placebo ⓘ |
| usedDuring | COVID-19 pandemic ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.